Viking Therapeutics over the weekend at the American Society for Bone and Mineral Research annual meeting presented full data from the positive Phase II study with VK5211 for the treatment of patients recovering from hip fracture, William Blair analyst Andy Hsieh tells investors in a research note. While top-line results were released late last year, there were incrementally positive data points, including 6-minute walk test improvements and "intriguing" fat mass reduction, Hsieh writes. He believes the updated clinical profile bodes well for the partnership potential for VK5211 and eventual market uptake. The analyst continues to hold a bullish view on Viking Therapeutics shares with an Outperform rating.

Virtual Meeting to be held on April 26 hosted by Truist.